Viñolas, Nuria http://orcid.org/0000-0001-5354-8553
Mezquita, Laura
Corral, Jesús
Cobo, Manuel
Gil-Moncayo, Francisco
Paz-Ares, Luis
Remon, Jordi
Rodríguez, María
Ruano-Raviña, Alberto
Conde, Esther
Majem, Margarita
Garrido, Pilar
Felip, Enriqueta
Isla, Dolores
de Castro, Javier
Article History
Received: 28 February 2023
Accepted: 20 June 2023
First Online: 25 July 2023
Declarations
:
: N Viñolas declares no conflict of interest. L Mezquita has not received any funding related to the content of this paper. J Corral has received education grants, provided consultation, attended advisory boards, and/or provided lectures for Amgen, AstraZeneca, Boehringer-Ingelheim, Bristol-Myers Squibb, Eli Lilly and Company, GlaxoSmithKline, Hoffmann-La Roche, Janssen-Cilag, Merck Sharp & Dohme, Pfizer, Sanofi, and Takeda Pharmaceutical Company. J Corral declares no conflict of interest. M Cobo has received consultancy or advisory roles from AstraZeneca, Boehringer-Ingelheim, Bristol-Myers Squibb, Eli Lilly and Company, Janssen-Cilag, Kyowa, Merck Sharp & Dohme, Novartis, Pfizer, Roche, Sanofi, and Takeda Pharmaceutical Company; has received research funding from Bristol-Myers Squibb; and has made speaking and public presentations on behalf of AstraZeneca, Boehringer-Ingelheim, Roche, Bristol-Myers Squibb, Eli Lilly and Company, Janssen-Cilag, Kyowa, Merck Sharp & Dohme, Novartis, Novocure, Pierre Fabre, Sanofi, and Takeda Pharmaceutical Company. F Gil-Moncayo declares no conflict of interest. L Paz-Ares has not received any funding related to the content of this paper. J Remon has not received any funding related to the content of this paper. M Rodríguez has received consultant fees from Abex and AstraZeneca. She has also received a grant from Intuitive Surgical not related to the current manuscript. A Ruano has not received any funding related to the content of this paper. He has received public funds to conduct research on lung cancer from different competitive grants awarded by the Instituto de Salud Carlos III and other public entities. E Conde has received research funding from Eli Lilly and Company, Roche, and Thermo Fisher Scientific and honoraria, consulting and/or travel support from AstraZeneca, Bristol-Myers Squibb, Eli Lilly and Company, Janssen-Cilag, Merck Sharp & Dohme, Pfizer, Roche, and Takeda Pharmaceutical Company. M Majem has received consultancy or advisory roles from AstraZeneca, Bristol-Myers Squibb, Boehringer-Ingelheim, Helsinn Therapeutics, Janssen Oncology, Merck Sharp & Dohme, Novartis, Pierre Fabre, Pfizer, Roche, Sanofi, and Takeda Pharmaceutical Company; research funding from AstraZeneca, Bristol-Myers Squibb, and Roche; and travel and accommodations expenses from AstraZeneca, Eli Lilly and Company, and Roche. P Garrido has received consultancy or advisory services from AbbVie, Amgen, AstraZeneca, Bayer, Bristol-Myers Squibb, Boehringer Ingelheim, Eli Lilly and Company, GlaxoSmithKline, Janssen-Cilag, Merck Sharp & Dohme, Novartis, Pfizer, Roche, and Takeda Pharmaceutical Company and has made speaking and public presentations on behalf of Amgen, AstraZeneca, Bristol-Myers Squibb, Boehringer Ingelheim, Janssen-Cilag, Medscape, Merck Sharp & Dohme, Novartis, Pfizer, Roche, Takeda Pharmaceutical Company, and TouchTime. E Felip has received grants or research funding contracts related to Oncology Innovation from Merck Healthcare KGaA and Fundación Merck Salud; consulting fees from Amgen, AstraZeneca, Bayer, BerGenBio, Bristol-Myers Squibb, Daiichi Sankyo, Eli Lilly and Company, GlaxoSmithKline, Hoffmann-La Roche, Janssen-Cilag, Merck Serono, Merck Sharp & Dohme, Novartis, Peptomyc, Pfizer, Sanofi, and Takeda Pharmaceutical Company; and payment or honoraria for lectures, presentations, speakers bureaus, manuscripts writing or educational events from Amgen, AstraZeneca, Bristol-Myers Squibb, Eli Lilly and Company, Hoffmann-La Roche, Janssen-Cilag, Medical Trends, Medscape, Merck Serono, Merck Sharp & Dohme, PeerVoice, Pfizer, Sanofi, Takeda Pharmaceutical Company, and Touch Oncology. E Felip is an independent member of the board of Grifols. D Isla has not received any funding related to the content of this paper. J de Castro has not received any funding related to the content of this paper.
: Not applicable.
: Not applicable.
: Not applicable.